MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GIGON, P. L.
Right arrow Articles by GILLETTE, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GIGON, P. L.
Right arrow Articles by GILLETTE, J. R.

Molecular Pharmacology, Vol 5, 109-122, Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics

Studies on the Rate of Reduction of Hepatic Microsomal Cytochrome P-450 by Reduced Nicotinamide Adenine Dinucleotide Phosphate: Effect of Drug Substrates

PHILIPPE L. GIGON 1, THEODORE E. GRAM 1, and JAMES R. GILLETTE 1

1 Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Optimum conditions are described for the assay of cytochrome P-450 reduction by NADPH in rat liver microsomes. The addition in vitro of chemical compounds which produce type I spectral changes markedly accelerated the initial rate of NADPH-linked cytochrome P-450 reduction, while the addition of compounds which elicit type II spectral changes significantly decelerated the rate. These changes occurred in the absence of appreciable changes in the absorbance of the cytochrome P-450—CO complex, suggesting that they are not due simply to differences in the extinction coefficients of the complexes. The acceleration produced by ethylmorphine, a type I compound, was much greater in hepatic microsomes from male rats than in microsomes from female rats; this differential enhancement may play a role in determining sex differences in drug metabolism. None of the type I compounds significantly influenced microsomal cytochrome c reductase activity at concentrations that produced maximal enhancement of cytochrome P-450 reduction. NADPH oxidation, measured in the absence of exogenous electron acceptors, was significantly increased by type I substances. Addition of type II compounds to microsomal suspensions either did not affect or decreased cytochrome c reductase and NADPH oxidase activities.

The data suggest that the complexes formed between cytochrome P-450 and type I compounds are more readily reduced by NADPH than is the endogenous hemoprotein. Possible mechanisms by which type II compounds inhibit the reduction of cytochrome P-450 are discussed.

Submitted on September 13, 1968




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Yamazaki, W. W. Johnson, Y.-F. Ueng, T. Shimada, and F. P. Guengerich
Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4. CHARACTERIZATION OF A RECONSTITUTED CYTOCHROME P450 3A4/NADPH-CYTOCHROME P450 REDUCTASE SYSTEM AND STUDIES WITH APO-CYTOCHROME b5
J. Biol. Chem., November 1, 1996; 271(44): 27438 - 27444.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
E. Rubin and C. S. Lieber
Alcoholism, Alcohol, and Drugs
Science, June 11, 1971; 172(3988): 1097 - 1102.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics